TABLE 4

Antibacterial efficacies of various aerosolized regimens used to treat P. aeruginosa lung infections in patients with cystic fibrosis compared to oral or intravenous treatment a

TABLE 4
  • a Efficacy endpoints are expressed as the change from the baseline, i.e., reduction, in P. aeruginosa CFU (log10 CFU/g) in sputum or change (percent) in FEV1 values (+, increase; −, decrease) (CPX DPI, ciprofloxacin dry powder for inhalation; CPX lip, ciprofloxacin liposomal formulation for inhalation; LVX, levofloxacin; TOB TIP, tobramycin inhalation dry powder; TOB TSI, tobramycin solution for inhalation; AMI, amikacin; AZLI, aztreonam lysine for inhalation; AZT, aztreonam; COL DPI, colistin dry powder for inhalation; COL, colistin).

  • b Change from baseline at day 28.

  • c Recorded at days 14 to 16.

  • d Two patients had a 5-log10 reduction of titers, etc.

  • e P. aeruginosa was not detectable at day 14 in 77% of patients.

  • f Combination therapy with another antipseudomonal agent.

  • g erad., eradicated; NR, not reported.